Clicky

Landos Biopharma, Inc.(LABP)

Description: Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases. The company also develops NX-13, a gut-restricted oral therapeutic that targets NOD-like receptor X1, a mitochondria-associated receptor associated with the modulation of inflammatory cytokines for UC and CD; and PX-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and rheumatoid arthritis. The company was founded in 2017 and is headquartered in Blacksburg, Virginia.


Keywords: Medicine Biopharmaceutical Clinical Medicine Autoimmune Disease Rheumatoid Arthritis Ulcerative Colitis Inflammatory Bowel Disease Crohn's Disease Gastroenterology Diarrhea Colitis Abdominal Pain Diabetic Nephropathy

Home Page: landosbiopharma.com

LABP Technical Analysis

1800 Kraft Drive
Blacksburg, VA 24060
United States
Phone: 540 218 2232


Officers

Name Title
Mr. Timothy M. Mayleben M.B.A. Principal Financial Officer & Director
Dr. Josep Bassaganya-Riera DVM, Ph.D. Advisor
Mr. Gregory Oakes Pres, CEO & Director
Mr. Patrick Truesdell Principal Accounting Officer
Dr. Fabio Cataldi M.D. Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.2437
Price-to-Sales TTM: 2.3706
IPO Date: 2021-02-04
Fiscal Year End: December
Full Time Employees: 46
Back to stocks